JP2016513104A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513104A5
JP2016513104A5 JP2015557484A JP2015557484A JP2016513104A5 JP 2016513104 A5 JP2016513104 A5 JP 2016513104A5 JP 2015557484 A JP2015557484 A JP 2015557484A JP 2015557484 A JP2015557484 A JP 2015557484A JP 2016513104 A5 JP2016513104 A5 JP 2016513104A5
Authority
JP
Japan
Prior art keywords
antibody
kir3dl2
polypeptide
ptcl
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015557484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513104A (ja
JP6360077B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/053340 external-priority patent/WO2014128221A1/en
Publication of JP2016513104A publication Critical patent/JP2016513104A/ja
Publication of JP2016513104A5 publication Critical patent/JP2016513104A5/ja
Application granted granted Critical
Publication of JP6360077B2 publication Critical patent/JP6360077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015557484A 2013-02-20 2014-02-20 末梢t細胞リンパ腫の処置における使用のためのkir3dl2に特異的に結合する化合物 Active JP6360077B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361766798P 2013-02-20 2013-02-20
US61/766,798 2013-02-20
US201361831809P 2013-06-06 2013-06-06
US61/831,809 2013-06-06
PCT/EP2014/053340 WO2014128221A1 (en) 2013-02-20 2014-02-20 A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma

Publications (3)

Publication Number Publication Date
JP2016513104A JP2016513104A (ja) 2016-05-12
JP2016513104A5 true JP2016513104A5 (cg-RX-API-DMAC7.html) 2017-02-02
JP6360077B2 JP6360077B2 (ja) 2018-07-18

Family

ID=50156759

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015557484A Active JP6360077B2 (ja) 2013-02-20 2014-02-20 末梢t細胞リンパ腫の処置における使用のためのkir3dl2に特異的に結合する化合物

Country Status (9)

Country Link
US (5) US20160002345A1 (cg-RX-API-DMAC7.html)
EP (3) EP2958941B1 (cg-RX-API-DMAC7.html)
JP (1) JP6360077B2 (cg-RX-API-DMAC7.html)
CN (1) CN105026427B (cg-RX-API-DMAC7.html)
AU (1) AU2014220668B2 (cg-RX-API-DMAC7.html)
CA (1) CA2899241C (cg-RX-API-DMAC7.html)
DK (3) DK3896088T3 (cg-RX-API-DMAC7.html)
ES (2) ES2730011T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014128221A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
RU2682449C2 (ru) 2012-09-19 2019-03-19 Иннейт Фарма Связывающие kir3dl2 агенты
DK3896088T3 (da) 2013-02-20 2025-09-29 Innate Pharma Behandling af perifert t-cellelymfom
US20160130346A1 (en) * 2013-05-29 2016-05-12 Institut National De La Sante Et De La Recherche Medicale Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3116908B1 (en) 2014-03-14 2019-06-26 Innate Pharma Humanized kir3dl2 antibodies
WO2016030488A1 (en) * 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
US10487153B2 (en) 2015-06-10 2019-11-26 National Research Council Of Canada Carbonic anhydrase IX-specific antibodies and uses thereof
EP3325967B1 (en) 2015-07-24 2019-12-04 Innate Pharma Methods for detecting tissue infiltrating nk cells
AU2017212739B2 (en) 2016-01-27 2024-03-21 Sutro Biopharma, Inc. Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates
MX390955B (es) * 2016-06-02 2025-03-19 Seagen Inc Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma.
WO2018073363A1 (en) * 2016-10-21 2018-04-26 Innate Pharma Treatment with anti-kir3dl2 agents
EP3658588A1 (en) * 2017-07-26 2020-06-03 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
CN108319816B (zh) * 2018-02-27 2021-04-23 广州大学 一种基于基因通路识别小分子核糖核酸的方法
BR112021014236A2 (pt) * 2019-01-22 2021-09-28 Innate Pharma Anticorpo, composição farmacêutica, kit e método para predizer ou avaliar a eficácia
WO2022214432A1 (en) * 2021-04-05 2022-10-13 Innate Pharma Immunohistochemistry methods and kir3dl2-specific reagents

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5599790A (en) * 1992-06-11 1997-02-04 The Scripps Research Institute Fibrinogen γ chain polypeptide and compositions thereof
AU717020B2 (en) 1996-05-03 2000-03-16 Immunomedics Inc. Targeted combination immunotherapy of cancer
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2001022972A2 (en) 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
AU1922902A (en) 2000-12-18 2002-07-01 Inst Nat Sante Rech Med Novel means for the diagnosis and therapy of CTCL
KR100911951B1 (ko) * 2001-08-23 2009-08-13 젠맵 에이/에스 인터루킨 15 (il-15)에 대하여 특이적인 인간 항체
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
JP2004126818A (ja) 2002-09-30 2004-04-22 Toshiba Corp 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
HUE033129T2 (en) * 2003-07-24 2017-11-28 Innate Pharma Sa Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1747237A4 (en) 2004-04-16 2008-05-21 Macrogenics Inc SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
CA2601417C (en) * 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
JP5295568B2 (ja) * 2005-01-06 2013-09-18 ノヴォ ノルディスク アー/エス Kir結合剤およびその使用方法
KR20080032065A (ko) 2005-06-03 2008-04-14 제넨테크, 인크. 푸코실화 수준이 조절된 항체의 생성 방법
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
FR2894982A1 (fr) 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
WO2007071829A2 (en) 2005-12-22 2007-06-28 Dermagene Oy Methods and means related to diseases
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
JP2009529331A (ja) 2006-03-10 2009-08-20 マクロジェニクス,インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
CA2660592C (en) 2006-05-26 2016-07-12 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
CA2664343C (en) * 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
EP2379598B1 (en) * 2009-01-19 2015-03-11 Innate Pharma Anti-kir3d antibodies
CA2767755C (en) * 2009-07-17 2021-10-12 Rigshospitalet Inhibitors of complement activation
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
JP2013533746A (ja) * 2010-07-06 2013-08-29 アベオ ファーマシューティカルズ, インコーポレイテッド 抗ron抗体
RU2682449C2 (ru) 2012-09-19 2019-03-19 Иннейт Фарма Связывающие kir3dl2 агенты
CA2881764C (en) * 2012-09-19 2022-08-16 Innate Pharma Kir3dl2 binding agents
DK3896088T3 (da) 2013-02-20 2025-09-29 Innate Pharma Behandling af perifert t-cellelymfom
US20160130346A1 (en) 2013-05-29 2016-05-12 Institut National De La Sante Et De La Recherche Medicale Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas
EP3116908B1 (en) 2014-03-14 2019-06-26 Innate Pharma Humanized kir3dl2 antibodies
WO2018073363A1 (en) 2016-10-21 2018-04-26 Innate Pharma Treatment with anti-kir3dl2 agents
BR112021014236A2 (pt) 2019-01-22 2021-09-28 Innate Pharma Anticorpo, composição farmacêutica, kit e método para predizer ou avaliar a eficácia

Similar Documents

Publication Publication Date Title
Gravett et al. Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells
Lundholm et al. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion
Logozzi et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients
Song et al. HIV protective KIR3DL1/S1-HLA-B genotypes influence NK cell-mediated inhibition of HIV replication in autologous CD4 targets
JP2018083821A5 (cg-RX-API-DMAC7.html)
JP2012143232A5 (cg-RX-API-DMAC7.html)
Valadez-Cosmes et al. Identification of novel low-density neutrophil markers through unbiased high-dimensional flow cytometry screening in non-small cell lung cancer patients
JP2020503891A5 (cg-RX-API-DMAC7.html)
WO2018023100A3 (en) Anti-idiotypic antibodies against anti-cd19 antibodies
MX2018002400A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
PH12013501177A1 (en) TNF-a BINDING PROTEINS
HK1249854A1 (zh) 用於治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
WO2012017082A3 (de) Anti-la antikörper und ihre anwendung zum immunotargeting
Wei et al. Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma
Endo et al. Ossifying fibromyxoid tumor presenting EP400-PHF1 fusion gene
WO2014037588A3 (en) Methods and compounds for preventing, treating and diagnosing an inflammatory condition
WO2018071796A2 (en) Compositions and methods for identifying functional anti-tumor t cell responses
Yang et al. Involvement of CD244 in regulating CD4+ T cell immunity in patients with active tuberculosis
CL2012001980A1 (es) Uso de un anticuerpo monoclonal anti-cd44 o fragmento de unión del mismo, en el tratamiento del carcinoma escamocelular de cabeza y cuello (hnscc) en un mamífero, donde el hnscc se distingue según la expresión de cd44.
RU2016124670A (ru) Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения
Lhuillier et al. Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9
Pereira Ribeiro et al. p16INK4a expression and immunologic aging in chronic HIV infection
JP2014507435A5 (cg-RX-API-DMAC7.html)
GB201021623D0 (en) Detection of acute myeloid leukaemia